To access this material please log in or register

Register Authorize

Is there a place for acetylsalicylic acid in primary prevention of cardiovascular diseases? Opinions differ

Ryazantseva E. E., Gendlin G. E., Melekhov A. V.
State Budgetary Educational Institution of Higher Professional Education, “N.I. Pirogov Russian National Research Medical University” of the RF Ministry of Health Care, Ostrovityanova 1, Moscow 117997

Keywords: aspirin, acetylsalicylic acid, primary prevention, risk of bleeding, cardiovascular events, cardiovascular risk

DOI: 10.18087/rhj.2014.4.1975

The issue of primary prevention for cardiovascular events is presently gaining growing attention since the resources annually allocated from the healthcare budget for treatment of heart diseases have been increasing every year. Development of effective cardiovascular prevention for patients at high risk should consistently and considerably reduce these expenses. Acetylsalicylic acid (ASA) has been long and successfully used in patients with cardiovascular diseases, primarily for secondary prevention. The many-year, salutary experience of using ASA in patients with existing cardiovascular abnormalities has logically suggested that ASA would be useful also in individuals who do not have heart disease but are at risk of its development. The possibility of expanding indications for the use of ASA induced a vast response in the scientific medium; debates on expediency of using ASA for primary prevention have been rather growing than fading. In this article we were focused on most interesting publications on this issue for the last year and tried to make some conclusions.
  1. Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC / AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63 (25 Pt B): 2889–934.
  2. Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014 Apr 10;370 (15):1422–31.
  3. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1997 Oct 21;96 (8):2751–3.
  4. Peto R, Gray R, Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988 Jan 30;296 (6618):313–6.
  5. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med. 1989 Jul 20;321 (3):129–35.
  6. Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр). Кардиоваскулярная терапия и профилактика, 2008;6 (приложение 4):40 с.
  7. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct;34 (38):2949–3003.
  8. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF / AHA / ACP / AATS / PCNA / SCAI / STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012 Dec 18;60 (24):e44–e164.
  9. Patrono C, Andreotti F, Arnesen H et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 2011 Dec;32 (23):2922–32.
  10. Parekh AK, Galloway JM, Hong Y, Wright JS. Aspirin in the secondary prevention of cardiovascular disease. N Engl J Med. 2013 Jan 17;368 (3):204–5.
  11. Hayden M, Pigone M, Phillips et al. Aspirin for primary prevention of cardiovascular events: a summary of the evidence for U. S. Preventive Services Task Force. Ann Intern Med. 2002;136 (2):161–172
  12. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U. S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150 (6):396–404.
  13. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J. 1998;19 (10):1434–1503.
  14. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика 2011;10 (6) приложение 2:1–64.
  15. Cleland JG. Is aspirin useful in primary prevention? Eur Heart J. 2013 Nov;34 (44):3412–8.
  16. Seshasai SR, Wijesuriya S, Sivakumaran R et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012 Feb 13;172 (3):209–16.
  17. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984;310 (18):1137–1140.
  18. Davies MJ, Thomas AC. Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 1985 Apr;53 (4):363–73.
  19. Moreno PR, Purushothaman KR, Fuster V et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation. 2004 Oct 5;110 (14):2032–8.
  20. Barger AC, Beeuwkes R 3rd. Rupture of coronary vasa vasorum as a trigger of acute myocardial infarction. Am J Cardiol. 1990 Nov 6;66 (16):41G-43G.
  21. Tenaglia AN, Peters KG, Sketch MH Jr, Annex BH. Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J. 1998 Jan;135 (1):10–4.
  22. Moulton KS, Vakili K, Zurakowski D et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A. 2003 Apr 15;100 (8):4736–41.
  23. Moulton KS. Plaque angiogenesis and atherosclerosis. Curr Atheroscler Rep. 2001 May;3 (3):225–33.
  24. Virmani R, Kolodgie FD, Burke AP et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005 Oct;25 (10):2054–61.
  25. Kolodgie FD, Gold HK, Burke AP et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 2003 Dec 11;349 (24):2316–25.
  26. Patrono C, Ciabattoni G, Patrignani P et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985 Dec;72 (6):1177–84.
  27. Davie AP, Love MP, McMurray JJ. Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. Clin Pharmacol Ther. 2000;67 (5):530–537
  28. Cleland JG. Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular disease. Am J Med. 2012 Feb;125 (2):e13.
  29. Cleland JG. Long-term aspirin for coronary artery disease: arewebeing deceived by a biased presentation of the evidence? Future Cardiol. 2010 Mar;6 (2):141–6.
  30. Ridker PM, Cook NR, Lee IM et al. A randomized trial of Low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005 Mar 31;352 (13):1293–304.
  31. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. 1998;351 (9118):1755–1762.
  32. McAlister FA1; Renin Angiotension System Modulator Meta-Analysis Investigators. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. Eur Heart J. 2012 Feb;33 (4):505–14.
  33. Cleland JG. Is aspirin 'TheWeakest Link' in cardiovascular prophylaxis. The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis. 2002 Jan-Feb;44 (4):275–92.
  34. Cleland JGF, Witte K, Thackray S. Bradykinin and ventricular function. Eur Heart J. 2000;2 (Suppl H): H20‑H29.
  35. Jardine MJ, Ninomiya T, Perkovic V et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010 Sep 14;56 (12):956–65.
  36. Мелехов А. В., Рязанцева Е. Е. Ацетилсалициловая кислота для первичной профилактики у пациентов с артериальной гипертензией. Лечащий врач. 2014;2:21–26.
  37. Guazzi M, Brambilla R, Reina G et al. Aspirin angiotensin converting enzyme inhibitor coadministration and mortality in patients with heart failure. Arch Intern Med. 2003 Jul 14;163 (13):1574–9.
  38. McAlister FA, Ghali WA, Gong Y et al. Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. Circulation. 2006 Jun 6;113 (22):2572–8.
  39. Hissett J, Folks B, Coombs L et al. Effects of changing guidelines on prescribing aspirin for primary prevention of cardiovascular events. J Am Board Fam Med. 2014 Jan-Feb;27 (1):78–86.
  40. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337: a1840. doi: 10.1136 / bmj.a1840.
  41. Ogawa H, Nakayama M, Morimoto T et al. Lowdose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008 Nov 12;300 (18):2134–41.
  42. Peto R, Buring J, Hennekens C et al. Antitrombotic Trialists (ATT) Collaboration. Aspirin in primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373 (9678):1849–1860.
  43. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2012;33 (13):1635–1701.
  44. Redberg RF, Benjamin EJ, Bittner V et al. ACCF / AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. J Am Coll Cardiol. 2009 Sep 29;54 (14):1364–405.
  45. Goff DC Jr, Lloyd-Jones DM, Bennett G et al. 2013 ACC / AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129 (25 Suppl 2):S49–73.
  46. Patrono C. Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither? Eur Heart J. 2013 Nov;34 (44):3403–11.
  47. Rothwell PM, Fowkes FG, Belch JF et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011 Jan 1;377 (9759):31–41.
  48. Rothwell PM, Price JF, Fowkes FG et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012 Apr 28;379 (9826):1602–12.
  49. Coghill AE, Newcomb PA, Potter JD. Aspirin use, colorectal cancer survival, and loss to follow-up.JAMA. 2009 Dec 16;302 (23):2549; author reply 2549–50.
  50. Cleland JG. Does aspirin really reduce the risk of colon cancer? Lancet. 2012 Apr 28;379 (9826):1586; author reply 1587.
  51. A Study of Cardiovascular Events in Diabetes (ASCEND). Available at: http://www.ctsu.ox.ac.uk / ascend (15 February 2013)
  52. De Berardis G, Sacco M, Evangelista V et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials. 2007 Aug 28;8:21.
  53. Nelson MR, Reid CM, Ames DA et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust. 2008 Jul 21;189 (2):105–9.
  54. Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE). Available at: http://www.arrivestudy.com / EN / (15 February 2013).
  55. Morgan G. Aspirin for the primary prevention of vascular events? Public Health. 2009 Dec;123 (12):787–8.
  56. Lanas A, Wu P, Medin J, Mills EJ. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol. 2011 Sep;9 (9):762–768.e6.
  57. Lanas A, Perez-Aisa MA, Feu F et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol. 2005 Aug;100 (8):1685–93.
  58. Pirmohamed M, James S, Meakin S et al. Adverse drug reacrions as a cause of admission to hospital: retrospective analysis of 18,820 patients. BMJ 2004;329:15–19.
  59. Gorelick PB, Weisman SM. Risk of haemorrhagic stroke with aspirin use. An update. Stroke. 2005 Aug;36 (8):1801–7.
  60. Park K, Bavry AA. Aspirin: its risks, benefits, and optimal use in preventing cardiovascular events. Cleve Clin J Med. 2013 May;80 (5):318–26.
  61. Grosser T, Fries S, Lawson JA et al. Drug resistance and pseudoresistance: An unintended consequence of enteric coating aspirin. Circulation. 2013 Jan 22;127 (3):377–85.
  62. Karha J, Rajagopal V, Kottke-Marchant K, Bhatt DL. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J. 2006 May;151 (5):976.e7–11.
Ryazantseva E. E., Gendlin G. E., Melekhov A. V. Is there a place for acetylsalicylic acid in primary prevention of cardiovascular diseases? Opinions differ. Russian Heart Journal. 2014;78 (4):246–255

To access this material please log in or register

Register Authorize
Ru En